Ionis Pharmaceuticals
the antisense pioneer; the FDA has accepted for Priority Review the New Drug Application for zilganersen in Alexander disease, and Ionis has licensed zilganersen to Recordati for all countries outside the US, extending its Spinraza (nusinersen, SMA) heritage.
- Country
- United States
- Ticker
- IONS
Commercial
Antisense oligonucleotide
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Nucleic acid therapeutics (oligonucleotides) | therapeutics-platforms | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.